Skip to main
GRAL

GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL Inc (GRAL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 13%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

GRAIL is expected to have positive data results at ASCO later this month with their multi-cancer early detection test, which could lead to a potential FDA approval and favorable reaction from oncologists. Despite facing guidance conservatism due to uncertainties with their digital health partners and sales force ramp, the company has shown strong revenue growth and has a favorable risk/reward profile. The company also has a wide range of potential revenue outcomes, with the biggest factor being FDA approval.

Bears say

GRAIL is facing challenges in gaining adoption from major health systems due to potential workflow friction, and its reliance on self-pay customers may not be sustainable once FDA approval is obtained. Additionally, there are risks associated with potential FDA approval delays or a more limited label, as well as potential setbacks in obtaining Medicare reimbursement. Revenue estimates have been adjusted slightly, but a neutral outlook is maintained for the stock due to the potential for a premium multiple in the underpenetrated MCED market and expected volume growth.

GRAIL Inc (GRAL) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRAIL Inc (GRAL) Forecast

Analysts have given GRAIL Inc (GRAL) a Buy based on their latest research and market trends.

According to 8 analysts, GRAIL Inc (GRAL) has a Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRAIL Inc (GRAL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.